Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Study confirms effecacy of EsophyX:

This article was originally published in Clinica

Executive Summary

A one-year follow-up of gastro-oesophageal reflux disease (GORD) patients who underwent transoral incisionless fundoplication (TIF) using EndoGastric Solutions' first-generation EsophyX device has found that 85% remained free of symptoms and did not require GORD medication such as proton pump inhibitors, thus confirming the results of earlier studies. Last year the Richmond, Washington-based company raised $30m to support the launch of the EsophyX device, which is now available throughout the US and EU.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT046371

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel